Risankizumab for treating moderate to severe plaque psoriasis

Mari Imamura; David Cooper; Rodolfo Andrés Hernández; Anthony Ormerod; Graham Scotland; Miriam Brazzelli; Aberdeen HTA Group

Risankizumab for treating moderate to severe plaque psoriasis

Mari Imamura, David Cooper, Rodolfo Andrés Hernández, Anthony Ormerod, Graham Scotland, Miriam Brazzelli^* (Corresponding Author), Aberdeen HTA Group

^*Corresponding author for this work

Research output: Book/Report › Commissioned Report

Original language	English
Publisher	National Institute for Health and Care Excellence (NICE)
Publication status	Published - 2019

Bibliographical note

Evidence Review Group report in support of NICE Fast Track Appraisal Programme. London: National Institute for Health and Care Excellence

Source of funding: This report was commissioned by the NIHR HTA Programme as
project number 127535

Access to Document

https://www.nice.org.uk/guidance/ta596/evidence/committee-papers-pdf-6895106173

Cite this

@book{a740fcdeee1441e6bc2f4a25480a45a9,

title = "Risankizumab for treating moderate to severe plaque psoriasis",

author = "Mari Imamura and David Cooper and Hern{\'a}ndez, {Rodolfo Andr{\'e}s} and Anthony Ormerod and Graham Scotland and Miriam Brazzelli and {Aberdeen HTA Group}",

note = "Evidence Review Group report in support of NICE Fast Track Appraisal Programme. London: National Institute for Health and Care Excellence Source of funding: This report was commissioned by the NIHR HTA Programme as project number 127535",

year = "2019",

language = "English",

publisher = "National Institute for Health and Care Excellence (NICE)",

}

TY - BOOK

T1 - Risankizumab for treating moderate to severe plaque psoriasis

AU - Imamura, Mari

AU - Cooper, David

AU - Hernández, Rodolfo Andrés

AU - Ormerod, Anthony

AU - Scotland, Graham

AU - Brazzelli, Miriam

AU - Aberdeen HTA Group

N1 - Evidence Review Group report in support of NICE Fast Track Appraisal Programme. London: National Institute for Health and Care Excellence Source of funding: This report was commissioned by the NIHR HTA Programme as project number 127535

PY - 2019

Y1 - 2019

M3 - Commissioned Report

BT - Risankizumab for treating moderate to severe plaque psoriasis

PB - National Institute for Health and Care Excellence (NICE)

ER -